Lupin acquires Huminsulin from Lilly to Enhance Diabetes Portfolio
Global pharma major Lupin Limited announced the acquisition of Huminsulin® in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.